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Abstract:
Every year 200,000 women in the United States are diagnosed with breast cancer.
Of the cases diagnosed, 10% -15% are classified as triple negative breast cancer (TNBC)
due to the absence of estrogen, progesterone, and HER-2/Neu receptors. This breast
cancer sub-type is markedly more aggressive and twice as likely to develop in
premenopausal women. TNBC is resistant to endocrine therapies and current targeted
agents, making clinical need for the development of validated therapeutics for TNBC a
pressing matter.

To initiate drug development, the internalization of directly

immunolabeled epidermal growth factor receptors (EGFR) in SK-BR-3 human breast
adenocarcinoma cells was quantitated using live-cell multiphoton microscopy for 30
minutes over 5 minute intervals. EGFR targeting is of interest because its internalization
triggers the signaling pathway that disrupts cell-cell adhesion and induces cell motility.
The images acquired were processed using ImageJ and analyzed through line profiles.
After measuring the full width half max at each time point of the 30-minute time series, it
was determined that significant EGFR internalization did not occur.

Key words: Epidermal growth factor receptor, Triple negative breast cancer, Multiphoton
microscopy
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1. INTRODUCTION
Breast cancer currently accounts for 15% of cancer-related deaths in women and
is the most common cancer in women worldwide. (1-2). In the United States alone, there
are 200,000 invasive breast cancer cases and 50,000 in situ breast cancer cases diagnosed
each year (1,3). Breast cancers can generally be categorized into three sub-types:
hormone receptor positive tumors, HER-2/Neu amplified tumors, or triple negative
tumors. The expression of estrogen receptors and progesterone receptors indicates
hormone receptor positive tumors. HER-2/Neu is a member of the epidermal growth
factor receptor (EGFR) family of tyrosine kinase receptors (RTK). Its overexpression
indicates HER-2/Neu amplified tumors. With triple negative tumors, however, all three of
these types of receptors are absent. Triple negative breast cancer (TNBC) makes up 10%15% of breast cancer cases, with women under 40 years old being twice a likely to
develop this subtype than women over 60 years old (1,4). There are 6 classifications of
TNBC that have been identified: basal-like (BL1 and BL2), immunomodulatory (IM),
mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor
(LAR).

These classifications are determined through immunohistochemistry and

fluorescence assessment using in situ hybridization technique. About 75% of TNBC
cases diagnosed are basal-like (5). TNBC is typically diagnosed as having a higher
histologic grade than other breast cancer types.

This higher grade indicates high

aggression, poor prognosis, increased recurrence three years after diagnosis, and high
five-year mortality.

Because TNBC lacks estrogen, progesterone, and HER-2/Neu

receptors, the treatment options available are limited due to tumors not responding to
endocrine therapies and current targeted agents (3-4).
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In TNBC cells, the
signaling

leading

to

invasiveness and metastasis is
known.

When

epidermal

growth factor (EGF) binds to
EGFR, the receptor dimerizes
and trans-phosphorylates the
Tyr1068 and Tyr1086 regions
of the receptor. This causes
GEP100, a guanine nucleotide
effector

protein,

to

be

recruited and its pleckstrin

Figure 1: Illustration of EGFR-GEP100-Arf6-AMAP1
signaling cascade seen in breast cancer leading to invasion
and metastasis. When EGF binds to EGFR, the Tyr1068 and
Tyr1086 regions of the receptor highly phosphorylate and
bind the pleckstrin homology domain of GEP100. Through
this binding, GEP100 activates and recruits Arf6 and
downstream signaling employs AMAP1 as its effector. This
signaling pathway causes E-cadherin-based cell-cell adhesion
to be disrupted.

homology domain to bind with the heavily phosphorylated regions of the EGFR. This
interaction causes Arf6 to be activated and to be recruited. Arf6 regulates endocytosis and
recycling of plasma membrane components and, when activated, causes cell metastasis,
invasion, and proliferation. AMAP1, an effector protein of the activated Arf6, is recruited
to interact with Arf6. This signaling cascade, shown in Figure 1, induces cells to develop
a motile phenotype, in which E-cadherin-based cell-to-cell adhesion is lost and the tumor
cells become invasive and metastatic (5-7). When a ligand binds to RTKs, they
experience ligand-enhanced internalization after 15 minutes into the endocytic pathway
and they continue signaling within endosomes (8-10).
The absence of well-defined molecular targets and the heterogeneity of the
disease make the clinical need for TNBC specific therapies imperative (11). To begin to
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develop validated therapeutic targets for TNBC, the cell biology behind EGFRs must be
clarified. To initiate this task, EGFR was fluorescently labeled in SK-BR-3 human breast
adenocarcinoma cells to quantify the amount of extra- and intracellular EGFR using livecell multiphoton microscopy.

2. MATERIALS AND METHODS
2.1 Cell Culture
SK-BR-3 cells, obtained from the American Type Culture Collection (ATCC),
were cultured in DMEM (ATCC) consisting of 10% fetal bovine serum (ATCC) and 5%
penicillin/streptomycin (Gibco) at 37°C in 5% CO2. Cells were passaged up to P4 to
maintain EGFR expression (12). At least 12 hours prior to image acquisition, the cells
were cultured onto 25 mm round coverslips (VWR) with 100,000 cells per mL under
serum-starved conditions in DMEM (ATCC) consisting of 10% charcoal stripped fetal
bovine serum (Gibco, cat. 12676-029) and 5% penicillin/streptomycin at 37°C in 5% CO2
(8).
2.2 Direct Immunolabeling
Prior to image acquisition, the serum-starved cells on the cover slip were directly
labeled with 10µg/mL Alexa Fluor 488-conjugated mouse anti-human ErbB2 monoclonal
antibodies (mAb) from Biolegend (clone: AY13, cat. 352907) or 10µg/mL Alexa Fluor
mouse mAb IgG1 control (clone: MOPC-21, cat. 400132) from Biolegend diluted in 1x
PBS with and DAPI for 30 minutes on ice in the dark. After incubation, the cells were
washed with 1x PBS three times. Once labeled, the cover slip was placed into an adapter
and 2mL of Tyrode’s buffer solution was added.
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2.3 Image Acquisition
Live-cell multiphoton imaging was performed using a Mai Tai femtosecond
pulsing Ti:Sapphire laser (Spectra Physics) and a 40x water immersion objective with a
0.8 NA (Nikon). An overview of the multiphoton microscope set-up used can be seen in
Figure 2.

Figure 2: Schematic overview of multiphoton microscope with a femtosecond pulsing
Ti:Sapphire laser and a 40x water immersion 0.8 NA objective.

All images were captured with an incident laser power of 20mW. Initially, the
DAPI stained nuclei were capture at a wavelength of 720nm at 200 frames per second
and 50% of maximum gain of photomultiplier tubes to properly align cells. Then, for the
live-cell study to capture the Alexa Fluor 488-conjugated mouse anti-human EGFR mAb
being internalized, a time series was established to image every 300 seconds for a total of
6 measurements (total time of 30 minutes). The images were acquired at 200 frames per
second with a laser wavelength of 930nm, using 50% of maximal gain of the
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photomultiplier tubes, and with a 512µm x 512µm acquisition field of view. Once the
time series was completed, the DAPI was imaged a second time with the same
parameters used initially at 720nm.

2.4 Image Analysis
Following acquisition, the images were loaded into ImageJ for analysis. The
images of the 3 time series captured were stacked and merged with their corresponding
DAPI image. This served to visualize the trafficking of EGFR and qualitatively
determine if internalization occurred. Then, lines were manually drawn through the
centers of 6 imaged cells to develop a line profile of EGFR location at each of the 6 time
points within the 30 minutes of the live-cell image capture at 930nm. The line profile
provided data for gray value of the image verses the length of the line drawn in microns.
From the graphs generated with this data, the full width half max (FWHM) was measured
from the peaks present. The average FWHM from the 6 cells at each time point was then
calculated and at t-test (p=0.05) was conducted between 5-minute and 30-minute time
point averages to determine if a statistical difference existed.

3. RESULTS AND DISCUSSION
After the images of the DAPI captured at 720nm and the time series images of
anti-EGFR captured at 930nm were acquired, they were merged to form a single image
for each time point within ImageJ. By observation of the cells in these merged images, it
appeared that the band of EGFR at the surface of the cell was thinner at the 5-minute time
point than it was at the 30-minute time point (Figure 3). It was believed this band
thickening was qualitative evidence of EGFR internalization.
7

Figure 3: Time series images of a live SK-BR-3 cell over a 30-minute period, showing 5
intervals. Cells were labeled with DAPI and anti-EGFR and images were acquired with an
excitation wavelength of 720nm and 930nm, respectively. Scale bar represents 10 microns.

To quantitate EGFR internalization, the line profiles of 6 cells imaged at 930nm
were collected for each time point. As seen in Figure 4 (A), there were 2 peaks at every
time point signifying the locations of the cell surface along the center-line drawn where
the EGFR was located. If internalization were occurring these peaks would theoretically
widen as time progressed. This widening was thought to have been qualitatively seen in
Figure 3. The data from the line profiles was collected in the form of gray value verses
distance. Once plotted, the FWHM was determined for the peaks present at all 6 time
points and averaged for each time point.
With all of the FWHM determined for each time point in 6 imaged cells, they
were then averaged and plotted in Figure 4 (B). A t-test was run to determine if there a
significant difference in the cell-surface EGFR band at 5 minutes and at 30 minutes. It
was determined that their widths were not significally different (p=0.05), thus there was
not a significant amount of EGFR internalized.
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Figure 4: A) Example of line profile of an image acquired at 930nm at the 5-minute time point
and the 30-minute time point. Peaks display EGFR initial and final location within cell. B) Plot
of the average FWHM of 6 cells over 30 minutes. The FWHM at 5 minutes and 30 minutes were
not significantly different (p=0.05).
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4. CONCLUSIONS
Triple negative breast cancer is an invasive breast cancer sub-type that currently
lacks targeted agents. Aiming to aid in the development of TNBC therapeutics, the
internalization of EGFR was quantified using live-cell multiphoton microscopy on SKBR-3 cells over 30 minutes. The cells were directly immunolabeled with Alexa Fluor
488-conjugated mouse anti-EGFR mAb and DAPI and imaged at 930nm and 720nm,
respectively. The resulting time series images qualitatively showed the internalization of
EGFR through the thickening of the EGFR band on the surface of the cell. When the
FWHM was taken for each time point within the series, however, it was quantitatively
shown that no significant amount of EGFR was internalized between the 5-minute and
30-minute time point.

5. FUTURE DIRECTIONS
Moving forward, this experiment will be duplicated using a higher incident power
during image acquisition. It is believed this will enable better visualization of EGFR
trafficking.

In addition, MDA-MB-468 cells, a TNBC cell line with EGFR

overexpression, will be used to quantify EGFR internalization.

The MDA-MB-468

results will be compared to the SK-BR-3 results to further determine the validity of
EGFR as a TNBC therapeutic target.
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